Deals In Depth: November 2015
Sanofi pushed ahead to advance its leadership in diabetes in a partnership with Hanmi; Pfizer bought Allergan in biopharma's biggest M&A to date, at $160bn. Boston Pharma's $600m financing contributed greatly to the early-stage venture category's 50% share of total financing.
You may also be interested in...
Coming year could feature first-time approvals in the EU for at least five gene therapies.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.